Dr. Michael Buschle

Dr Michael Buschle

Chief Scientific Officer, Glenmark Pharmaceuticals Ltd.

Education

Doctorate

University Of London

Other Affiliations

Intercell Ag

University Of London

Glenmark Pharmaceuticals S.A

Local Address: La Chaux-de-Fonds, Switzerland

Glenmark Pharmaceuticals Limited 
750 Corporate Drive 

Mahwah , New Jersey 07430

United States 

Dr. Michael Buschle has been Chief Scientific Officer of Glenmark Pharmaceuticals Ltd. Dr. Buschle serves as President for Biologics Research at Glenmark Pharmaceuticals S.A. 

He served as President for Biologics Research at Glenmark Pharmaceuticals Ltd. Mr. Buschle served as Chief Scientific Officer of Intercell Biomedical Research & Development AG. Dr. Buschle served as Director and Managing Director of Intercell Biomedical Ltd., a subsidiary of Intercell AG. 

He served as Chief Technical Officer of Intercell AG, since November 2004 and prior to this served as Chief Scientific Officer. Dr. Buschle served as a Member of Management Board of Intercell Biomedical Research & Development AG until October 24, 2005. 

Dr Michael Buschle

Mr. Buschle scientific and industrial career includes work at Royal Free Hospital School of Medicine, London, UK, the St. Jude Children’s Research Hospital, Memphis, TN, USA and at pharmaceutical company Boehringer Ingelheim. He was one of the co-founders of Intercell AG. During his time at Boehringer Ingelheim, he was involved in the development of a cancer vaccine against malignant melanomas. Mr. Buschle is the holder of several patents in the field of vaccines and biotechnology. 

Mr. Buschle is responsible for its Core Research activities leading to development candidates. Dr. Buschle has over 12 years of pharmaceutical/biotech industry experience in areas including drug research and development and biopharmaceuticals manufacturing. Dr. Buschle holds a doctorate from the University of London.

Dr Anthony crasto With Dr Michael Buschle end 2014

Summary

Dr. Michael Buschle is Chief Scientific Officer at Glenmark Pharmaceuticals Ltd. Dr. Buschle was previously employed as Co-Founder by Intercell AG.

Current positions of Michael Buschle, PhD

Name Title Since  Glenmark Pharmaceuticals Ltd (Pharmaceuticals) Chief Scientific Officer 2012

Company Description: 

Glenmark US Operations Glenmark Pharmaceuticals has established its US subsidiary, based in Princeton, New Jersey, Glenmark Pharmaceuticals Inc., USA, to help file ANDAs and market finished formulations in the lucrative US market. Glenmark Pharmaceuticals Inc., USA will file Paragraph III and Paragraph IV ANDA filings for approval to market generic drugs, and work in tandem with other companies in marketing partnerships, to establish market penetration and substantial marketshare in the US market. Glenmark will make a number of such filings over the next 18 to 24 months. Further the company will register its bulk drugs - the key ingredients that lend medicines their potency - with the US Food & Drug Administration. It plans four to five drug master filings in the US this year, with the first likely to happen in the second quarter ending September. With these strategic initiatives underway, the Company is aggressively looking at additional strategic partnerships with other leading generic drug companies with a strong US presence.

//////////////

CLICK TO PLAY

Published on 21 Aug 2014

Mint met with Michael Buschle, Chief Scientific Officer & President of Biologics, Glenmark Pharmaceuticals to discuss costs, challenges and selecting regions for trials in India.

“Researchers at Glenmark focus on developing monoclonal antibodies. Glenmark is the first Indian company that has a novel, first-in-class novel biologic entity in the clinics in the US. We are establishing platform technologies to develop biologics in a format specific for Glenmark”

-Dr Michael Buschle, president (biologics), Glenmark Pharmaceuticals
- See more at: http://www.biospectrumindia.com/biospecindia/news/158971/master-innovation#sthash.k9A3A07N.dpuf

MD and CEO Glenn Saldanha with Michael Buschle, President Biologics, Glenmark Pharmaceuticals Ltd.



PICTURES











SWITZERLAND










Mahwah , New Jersey 

1. 
   

   
3. Mahwah

   Township in New Jersey

dollar 22 Million English Manor in Mahwah New Jersey


La Chaux-de-Fonds, Switzerland

1. 

   1. • 
2. La Chaux-de-Fonds

1. 1. • 
2. Intercell

   Biotechnology company
3. Intercell AG was a biotechnology company based in Vienna which focuses on the development of modern prophylactic and therapeutic vaccines against infectious diseases. Wikipedia
5. Headquarters: Vienna, Vienna, Austria
6. Founded: 1998

Christine Le

 Toronto organic chemist Christine Le has developed a more efficient and environmentally friendly method of manufacturing a potential anti-cancer drug.

Toronto Organic chemist Christine Le has developed a more efficient and environmentally friendly method of manufacturing a potential anti-cancer drug.

Christine Le is talking about cooking. It isn’t long before the conversation collides with her other passion: molecules.
She is describing a recent visit to Alinea, the world-renowned Chicago restaurant that uses a cooking style called molecular gastronomy to create new flavours and textures in food. The restaurant is known for using liquid nitrogen and helium in its dishes.
“I thought [the food] was great, but you definitely have to have an open mind to it,” she says.
It is her curious mind that has just earned the University of Toronto PhD candidate a place on Forbes‘ “Top 30 Under 30” list for science. She is the only Canadian on the list, described by Forbes as the “greatest gathering of young game changers, movers and makers.”
The 26-year-old organic chemist is being recognized for discovering an efficient way to recreate molecules found naturally in plants. Her discovery could fight cancer at its source by decreasing abnormal cell growth.
“One reaction she pioneered uses rhodium to speed the production of eight medicinal compounds, including an anti-cancer drug candidate,” Forbes notes.

James MacDonald for National PostChristine Le in her lab at the University of Toronto campus.

Ms. Le, who worked on this synthesis during her year completing a master’s degree at U of T, says that while she and her team did not discover the molecule — named cytosporone B — they developed a way to create it that reduces the amount of hazardous waste generated in the production.
“You can’t get a large quantity of these molecules because nature only produces small amounts. In the lab we try to mimic the compound,” explains Ms. Le.
The molecule is a naturally occurring compound that is isolated from a Costa Rican fungus. Previous studies on cytosporone B have shown that it has the ability to activate a receptor that controls cell death in live mice.
“When you invent a new reaction you look for a way to shorten the number of steps it takes to make a molecule of interest. Ideally, you also want to reduce the amount of waste that you produce. So if you take fewer steps and use reaction conditions that produce less waste, then that is best of all,” says Mark Lautens, Ms. Le’s professor and an Order of Canada recipient for his contributions to organic chemistry.
The molecule can now be made in three steps, saving time, money and resources. In addition to reducing chemical waste in the manufacturing process, her method yields the most molecules. “The final step of our method to create cytosporone B, and related compounds, is completely ‘atom-economical,’ meaning that all the atoms in the starting materials are conserved in the product and no wasteful by-products are produced,” says Ms. Le, who was named to Scientific American journal’s “30 under 30” list in 2013.

‘Our motivation lies in what we can create, but our interest and our passion for chemistry stems from what we can discover and learn along the way’

In October, Forbes is holding a summit in Philadelphia so the members of the “30 under 30” list can connect. “It will be great stepping out of this bubble and meeting people in diverse industries,” says Ms. Le, adding that she hopes to combine her scientific background with more business or technology-oriented people.
The daughter of a single mother who works as hairdresser, Ms. Le grew up in Richmond Hill with two older half-brothers. She realized she had a passion for science at a young age, ironically through television. Her favourite shows were Popular Mechanics for Kids, Bill Nye the Science Guy and The Magic School Bus.
Ms. Le says she hopes to inspire the next generation of chemists, much like her teachers at Cardinal Carter Catholic High School in Aurora did for her, by tutoring. She is still driven by the same natural curiosity that her students have.
“I want to understand the world around me on a microscopic level,” she says. “Our motivation lies in what we can create, but our interest and our passion for chemistry stems from what we can discover and learn along the way.”
 
 
Christine Le cle@chem.utoronto.ca

Ph.D Student (July 2012)
M.Sc. University of Toronto
B.Sc. University of Western Ontario 

Christine Le Named to Forbes' Top 30 Under 30 Science List

Christine Le (Lautens' group) has been named to the Forbes’ Top 30 Under 30 Science list. She’s been cited as a rising star by Forbes for her research on designing more efficient and environmentally-friendly methods to create molecules that are mainly used by pharmaceutical drug and chemical manufacturing industries.
To read more about Christine, please visit, http://news.artsci.utoronto.ca/news/chemistry-phd-candidate-forbes-top-30-under-30-science-list/.

Christine Le (@christine_m_le)  



https://www.linkedin.com/profile/view?id=234501529


Toronto

University of Toronto

University in Toronto, Ontario

 
 





Through this committee, you can help maintain and protect the Soldiers' Tower, a 143-ft. tall stone monument to the sacrifices of these servicemen and ...